Technical Analysis for LNTH - Lantheus Holdings, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 69.48 | -0.07% | -0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | -0.07% | |
| Multiple of Ten Bearish | Other | -0.07% | |
| Above Upper BB | Strength | -0.07% | |
| Overbought Stochastic | Strength | -0.07% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 12 hours ago |
| 50 DMA Resistance | about 12 hours ago |
| Gap Up Closed | about 13 hours ago |
| Gap Up Partially Closed | about 13 hours ago |
| Down 1% | about 13 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/01/2023
Lantheus Holdings, Inc. Description
Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Company's products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Company's products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Disease Chemical Elements Prostate Cancer Heart Failure Medical Imaging Stroke Medical Physics Perfusion Artery Radiopharmaceuticals Artery Disease Congestive Heart Failure Imaging Agent Peripheral Vascular Disease Coronary Artery Disease Gallium Neuron Cardiovascular And Other Diseases Medicinal Radiochemistry Myocardial Perfusion Imaging
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 100.8505 |
| 52 Week Low | 47.46 |
| Average Volume | 1,019,100 |
| 200-Day Moving Average | 74.22 |
| 50-Day Moving Average | 70.06 |
| 20-Day Moving Average | 65.09 |
| 10-Day Moving Average | 64.62 |
| Average True Range | 2.49 |
| RSI (14) | 57.98 |
| ADX | 28.7 |
| +DI | 29.56 |
| -DI | 19.96 |
| Chandelier Exit (Long, 3 ATRs) | 62.96 |
| Chandelier Exit (Short, 3 ATRs) | 67.33 |
| Upper Bollinger Bands | 69.77 |
| Lower Bollinger Band | 60.41 |
| Percent B (%b) | 0.97 |
| BandWidth | 14.37 |
| MACD Line | -0.74 |
| MACD Signal Line | -1.80 |
| MACD Histogram | 1.0636 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 72.48 | ||||
| Resistance 3 (R3) | 72.47 | 71.45 | 71.98 | ||
| Resistance 2 (R2) | 71.45 | 70.69 | 71.46 | 71.81 | |
| Resistance 1 (R1) | 70.47 | 70.22 | 69.96 | 70.48 | 71.65 |
| Pivot Point | 69.45 | 69.45 | 69.20 | 69.46 | 69.45 |
| Support 1 (S1) | 68.47 | 68.69 | 67.96 | 68.48 | 67.31 |
| Support 2 (S2) | 67.45 | 68.22 | 67.46 | 67.15 | |
| Support 3 (S3) | 66.47 | 67.45 | 66.98 | ||
| Support 4 (S4) | 66.48 |
